increases toxicity of ibutilide by QTc interval. Avoid or Use Alternate Drug.idelalisibidelalisib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesiloperidoneescitalopram increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug.imipramineescitalopram and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.inotuzumabescitalopram increases toxicity of inotuzumab by QTc interval. Avoid or Use Alternate Drug.isofluraneisoflurane and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.ivosidenibivosidenib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ivosidenib will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.levomilnacipranescitalopram and levomilnacipran both increase serotonin levels. Avoid or Use Alternate Drug.linezolidlinezolid and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.lofepramineescitalopram and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.lonafarniblonafarnib will increase the level or effect of escitalopram by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Lonafarnib may increase the AUC and peak concentration of CYP2C19 substrates. If coadministration unavoidable, monitor for adverse reactions and reduce the CYP2C19 substrate dose in accordance with its approved product labeling.lopinavirescitalopram increases toxicity of lopinavir by QTc interval. Avoid or Use Alternate Drug.lorcaserinescitalopram and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.macimorelinmacimorelin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilineescitalopram and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.mefloquinemefloquine increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.meperidineescitalopram and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.meperidine, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.methadoneescitalopram increases toxicity of methadone by QTc interval. Avoid or Use Alternate Drug.methylene bluemethylene blue and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.metoclopramidemetoclopramide and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactionsmetoclopramide intranasalescitalopram, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.milnacipranescitalopram and milnacipran both increase serotonin levels. Avoid or Use Alternate Drug.mirtazapinemirtazapine and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.mobocertinibmobocertinib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.morphinemorphine, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.nefazodoneescitalopram and nefazodone both increase serotonin levels. Avoid or Use Alternate Drug.nefazodone will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.netupitant/palonosetronnetupitant/palonosetron, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.nilotinibescitalopram increases toxicity of nilotinib by QTc interval. Avoid or Use Alternate Drug.nortriptylineescitalopram and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.olopatadine intranasalescitalopram and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. ondansetronescitalopram and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.ondansetron, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.osimertinibescitalopram increases toxicity of osimertinib by QTc interval. Avoid or Use Alternate Drug.oxaliplatinoxaliplatin and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.ozanimodozanimod increases toxicity of escitalopram by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.paliperidoneescitalopram increases toxicity of paliperidone by QTc interval. Avoid or Use Alternate Drug.palonosetronpalonosetron, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.panobinostatescitalopram and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.paroxetineescitalopram and paroxetine both increase serotonin levels. Avoid or Use Alternate Drug.pazopanibescitalopram increases toxicity of pazopanib by QTc interval. Avoid or Use Alternate Drug.pentamidineescitalopram increases toxicity of pentamidine by QTc interval. Avoid or Use Alternate Drug.phentermineescitalopram, phentermine. Either increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome.pimavanserinescitalopram increases toxicity of pimavanserin by QTc interval. Avoid or Use Alternate Drug.pitolisantescitalopram and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.procainamideescitalopram increases toxicity of procainamide by QTc interval. Avoid or Use Alternate Drug.protriptylineescitalopram and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug.quetiapineescitalopram increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug.quinidineescitalopram increases toxicity of quinidine by QTc interval. Avoid or Use Alternate Drug.rasagilinerasagiline and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.remifentanilremifentanil, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.ribociclibribociclib increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug.escitalopram increases toxicity of ribociclib by QTc interval. Avoid or Use Alternate Drug.ropeginterferon alfa 2bropeginterferon alfa 2b, escitalopram. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.saquinavirescitalopram increases toxicity of saquinavir by QTc interval. Avoid or Use Alternate Drug.saquinavir will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.selegiline transdermalselegiline transdermal and escitalopram both increase serotonin levels. Avoid or Use Alternate Drug.selinexorselinexor, escitalopram. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sertralineescitalopram and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.escitalopram increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug.sevofluranesevoflurane and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.siponimodsiponimod and escitalopram both increase QTc interval. Avoid or Use Alternate Drug.sorafenibescitalopram increases toxicity of sorafenib by QTc interval. Avoid or Use Alternate Drug.sotalolescitalopram and sotalol both increase QTc interval. Avoid or Use Alternate Drug.St John's Wortescitalopram and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.sufentanilsufentanil, escitalopram. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.tedizolidtedizolid, escitalopram. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.tetrabenazineescitalopram increases toxicity of tetrabenazine by QTc interval. Avoid or Use Alternate Drug.toremifeneescitalopram increases toxicity of toremifene by QTc interval. Avoid or Use Alternate Drug.trazodoneescitalopram and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.trimipramineescitalopram and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.triptorelintriptorelin increases toxicity of escitalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.tucatinibtucatinib will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.umeclidinium bromide/vilanterol inhaledescitalopram increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vandetanibescitalopram, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.vemurafenibvemurafenib and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.escitalopram increases toxicity of vemurafenib by QTc interval. Avoid or Use Alternate Drug.venlafaxineescitalopram and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.vilanterol/fluticasone furoate inhaledescitalopram increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vilazodoneescitalopram, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .vortioxetineescitalopram, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.Monitor Closely (246)5-HTPescitalopram and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.aceclofenacescitalopram, aceclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.acemetacinescitalopram, acemetacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.albuterolalbuterol and escitalopram both increase QTc interval. Use Caution/Monitor.alfuzosinescitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and escitalopram both increase QTc interval. Use Caution/Monitor.almotriptanalmotriptan, escitalopram. Either increases toxicity of the other by serotonin levels. Modify Therapy/Monitor Closely. Exercise caution when concomitantly using agents that enhance serotonin activity. Monitor for the development of serotonin toxicity/serotonin syndrome during such therapy.amifampridineescitalopram increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amobarbitalamobarbital will decrease the level or effect of escitalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.amoxapineescitalopram increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.anagrelideanagrelide and escitalopram both increase QTc interval. Use Caution/Monitor.apixabanescitalopram increases effects of apixaban by anticoagulation. Use Caution/Monitor. SSRIs may inhibit platelet aggregation, thus increase bleeding risk when coadministered with anticoagulants.apomorphineescitalopram increases toxicity of apomorphine by QTc interval. Use Caution/Monitor.arformoterolescitalopram increases toxicity of arformoterol by QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and escitalopram both increase QTc interval. Use Caution/Monitor.aspirinescitalopram, aspirin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.aspirin rectalescitalopram, aspirin rectal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.aspirin/citric acid/sodium bicarbonateescitalopram, aspirin/citric acid/sodium bicarbonate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.atazanaviratazanavir increases